Skip to content
Relatix Health

Relatix Health

Radically different

  • Participate
    • Start here
  • Services
    • Tests to participate in
  • Resources
  • About
    • Our Vision – A radically different future
    • Our mission – personalised lifelong support
    • News
    • FAQ
    • Contact
    • Trust and Privacy
    • Support us
  • Log in / Sign up
Posted on July 24, 2026 by admin

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study

Nature Medicine, Published online: 24 July 2026; doi:10.1038/s41591-026-04496-2

In the LITMUS study, serum biomarkers outperformed imaging for identifying patients at risk of MASH, whereas elastography was superior for staging advanced fibrosis and cirrhosis.

CategoriesUncategorized TagsAcademic research, Biomarker, News Approved

Post navigation

Previous PostPrevious A new, separate outbreak of the diarrhea-causing parasite
Next PostNext AI-based clinician decision support system for diagnosis of inherited retinal diseases: a multicenter, randomized trial
Relatix Health

Relatix Health helps people understand their minds, explore relevant support and take part in research on their own terms. We connect lived experience with responsible research while protecting privacy, dignity and choice.

For researchers, clinicians and organisations, visit our sister site, Relatix Bio.

Take part

Start here Participate Tests to participate in Log in or sign up

Find support

Resources Services FAQ I need help now

Our commitments

Our Vision Our Mission Trust and Privacy

About

About us News Support us Contact

© 2026 Relatix Health. All rights reserved.